SG Americas Securities LLC Trims Stock Position in Kymera Therapeutics, Inc. $KYMR

SG Americas Securities LLC lessened its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) by 86.1% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,163 shares of the company’s stock after selling 19,530 shares during the period. SG Americas Securities LLC’s holdings in Kymera Therapeutics were worth $263,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Kymera Therapeutics by 6.3% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,793 shares of the company’s stock valued at $849,000 after purchasing an additional 1,833 shares during the period. Millennium Management LLC increased its holdings in shares of Kymera Therapeutics by 340.4% in the first quarter. Millennium Management LLC now owns 510,480 shares of the company’s stock worth $13,972,000 after purchasing an additional 394,562 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Kymera Therapeutics by 121.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 896,404 shares of the company’s stock worth $24,535,000 after purchasing an additional 491,737 shares during the period. Invesco Ltd. raised its position in shares of Kymera Therapeutics by 13.8% in the second quarter. Invesco Ltd. now owns 47,884 shares of the company’s stock worth $2,090,000 after buying an additional 5,809 shares in the last quarter. Finally, Sei Investments Co. purchased a new stake in shares of Kymera Therapeutics in the second quarter worth $265,000.

Kymera Therapeutics Stock Up 0.3%

Kymera Therapeutics stock opened at $119.35 on Friday. Kymera Therapeutics, Inc. has a twelve month low of $36.65 and a twelve month high of $130.05. The company has a market capitalization of $9.82 billion, a P/E ratio of -33.43 and a beta of 1.95. The stock’s 50 day moving average is $90.61 and its 200 day moving average is $84.32.

Kymera Therapeutics (NASDAQ:KYMR) last released its earnings results on Thursday, April 30th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.18. Kymera Therapeutics had a negative return on equity of 24.71% and a negative net margin of 611.94%.The business had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same period in the previous year, the company posted ($0.82) earnings per share. The company’s revenue for the quarter was up 55.5% compared to the same quarter last year. As a group, equities analysts expect that Kymera Therapeutics, Inc. will post -3.28 EPS for the current year.

Insider Activity

In related news, CEO Nello Mainolfi sold 80,000 shares of the stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $115.29, for a total transaction of $9,223,200.00. Following the sale, the chief executive officer directly owned 666,568 shares of the company’s stock, valued at approximately $76,848,624.72. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Bruce N. Jacobs sold 77,109 shares of the firm’s stock in a transaction dated Tuesday, June 30th. The shares were sold at an average price of $114.96, for a total transaction of $8,864,450.64. Following the sale, the chief financial officer owned 244,883 shares of the company’s stock, valued at approximately $28,151,749.68. This represents a 23.95% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 3,661,505 shares of company stock worth $392,385,535. 15.98% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms recently commented on KYMR. Canaccord Genuity Group boosted their target price on Kymera Therapeutics from $106.00 to $129.00 and gave the stock a “buy” rating in a research report on Friday, June 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Loop Capital set a $97.00 price target on shares of Kymera Therapeutics in a report on Monday, June 8th. Brookline Capital Markets reaffirmed a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Finally, Wall Street Zen upgraded Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $121.41.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.